CR20230413A - Moduladores de sting (estimulador de genes de interferón) - Google Patents

Moduladores de sting (estimulador de genes de interferón)

Info

Publication number
CR20230413A
CR20230413A CR20230413A CR20230413A CR20230413A CR 20230413 A CR20230413 A CR 20230413A CR 20230413 A CR20230413 A CR 20230413A CR 20230413 A CR20230413 A CR 20230413A CR 20230413 A CR20230413 A CR 20230413A
Authority
CR
Costa Rica
Prior art keywords
sting
stimulator
modulators
interferon genes
compounds
Prior art date
Application number
CR20230413A
Other languages
English (en)
Inventor
Ketan Satish Gajiwala
Chan Woo Huh
Ryan Lloyd Patman
Martin James Wythes
Mehran Jalaie
Jianmin Sun
Eugene Yuanjin Rui
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR20230413A publication Critical patent/CR20230413A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente se proporcionan compuestos de la Fórmula general (I):<br /> <img alt="" src="data:image/png;base64,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 (***)
CR20230413A 2021-03-18 2022-03-15 Moduladores de sting (estimulador de genes de interferón) CR20230413A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162640P 2021-03-18 2021-03-18
US202163165459P 2021-03-24 2021-03-24
PCT/IB2022/052300 WO2022195462A1 (en) 2021-03-18 2022-03-15 Modulators of sting (stimulator of interferon genes)

Publications (1)

Publication Number Publication Date
CR20230413A true CR20230413A (es) 2023-10-13

Family

ID=80819922

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230413A CR20230413A (es) 2021-03-18 2022-03-15 Moduladores de sting (estimulador de genes de interferón)

Country Status (17)

Country Link
US (1) US11964978B2 (es)
EP (1) EP4308563A1 (es)
JP (1) JP2024509982A (es)
KR (1) KR20230146606A (es)
AU (1) AU2022238001A1 (es)
BR (1) BR112023017731A2 (es)
CA (1) CA3213427A1 (es)
CL (1) CL2023002737A1 (es)
CO (1) CO2023012198A2 (es)
CR (1) CR20230413A (es)
DO (1) DOP2023000194A (es)
EC (1) ECSP23070418A (es)
IL (1) IL306034A (es)
MX (1) MX2023010942A (es)
TW (1) TWI829112B (es)
UY (1) UY39676A (es)
WO (1) WO2022195462A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222644A1 (en) 2022-05-18 2023-11-23 F. Hoffmann-La Roche Ag Pyrazole derivatives as sting agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20190031765A1 (en) 2016-01-25 2019-01-31 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
US10975287B2 (en) 2016-04-07 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
CA3024482A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
EP3642198B1 (en) 2017-06-22 2022-03-16 Curadev Pharma Limited Small molecule modulators of human sting
TWI741268B (zh) * 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑
WO2020028565A1 (en) * 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
PE20220166A1 (es) 2019-03-05 2022-01-28 F Star Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de enfermedad
CN114302875A (zh) 2019-05-16 2022-04-08 斯汀塞拉股份有限公司 氧代吖啶基乙酸衍生物及使用方法
AU2020355343B2 (en) 2019-09-25 2023-11-30 Pfizer Inc. Polyheterocyclic modulators of STING (stimulator of interferon genes)

Also Published As

Publication number Publication date
AU2022238001A1 (en) 2023-09-14
CA3213427A1 (en) 2022-09-22
IL306034A (en) 2023-11-01
TWI829112B (zh) 2024-01-11
KR20230146606A (ko) 2023-10-19
MX2023010942A (es) 2023-09-28
EP4308563A1 (en) 2024-01-24
UY39676A (es) 2022-10-31
US11964978B2 (en) 2024-04-23
CO2023012198A2 (es) 2023-11-30
TW202246262A (zh) 2022-12-01
WO2022195462A1 (en) 2022-09-22
BR112023017731A2 (pt) 2023-10-03
US20220306641A1 (en) 2022-09-29
CL2023002737A1 (es) 2024-04-01
JP2024509982A (ja) 2024-03-05
ECSP23070418A (es) 2023-10-31
DOP2023000194A (es) 2023-11-30

Similar Documents

Publication Publication Date Title
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
PH12020551486A1 (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
CR20210627A (es) Derivados de benzisoxazol sulfonimada
WO2019043634A3 (en) CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
MX2020010407A (es) Benzotiofenos y compuestos relacionados como agonistas de sting.
MX2022003633A (es) Moduladores poliheterociclicos de sting (estimulador de genes de interferon).
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2022006958A (es) Compuestos de quinazolinilo sustituidos utiles como activadores de celulas t.
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
MX2021015188A (es) Moduladores de nueva generacion del estimulador de genes de interferon (sting).
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton&#39;s tyrosine kinase
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EP4342473A3 (en) Compounds useful in hiv therapy
WO2021079196A3 (en) Mettl3 modulators
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2021014680A (es) Derivado de benzotriazol.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
CR20230413A (es) Moduladores de sting (estimulador de genes de interferón)
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
CR20210173A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen